Sm04554
Collapse
X
-
Comment
-
-
Bim a much better version of Minoxidil
SM i'm not sure? Isn't it a similar anti-androgen like CB?
Either way we seem to be in the early stages of simply upgrading older medication, nothing wrong with that, younger generations will be able to hold on to their hair and possibly grow a little back, still nothing that will turn a NW7-NW1 though.Comment
-
I agree, CB the new version of FIN/DUT without the sides.
Bim a much better version of Minoxidil
SM i'm not sure? Isn't it a similar anti-androgen like CB?
Either way we seem to be in the early stages of simply upgrading older medication, nothing wrong with that, younger generations will be able to hold on to their hair and possibly grow a little back, still nothing that will turn a NW7-NW1 though.Comment
-
Follica better hurry up and get a treatment to market, unless they want another effective topical getting there first.Comment
-
I don't think Follica has any intention of putting anything hair loss related to market. As Cotsarelis said to Desmond, they don't have the money...Comment
-
The only way they would be able to tell if they'd been making progress with other chemicals other than a gpr44 blocker, would be use a topical gpr44 blocker and test compounds. It's a crucial part of even testing their ability to regenerate new follicles, because they would have to block what's inhibiting hair growth in the first place and then add growth factors. Cotsarelis has said himself that they made it through two trials, and I think that would infer that they have something to block that receptor. If it costs "$2 million to produce," and would make billions every year, why wouldn't any of that $55 million go to Follica?
Not saying they'll have anything for sure, but I like what I see.Comment
-
This is the most exciting prospect in my opinion. It's based on the latest knowledge about aga and not all those prehistoric (only) dht stuff. 2015 will be the year where we will find out if any of sm, bim and cb will make it go through phase 3 (soon on market).Comment
Comment